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Release of fibrinopeptide B from fibrinogen by copperhead venom procoagulant enzyme results in a
form of fibrin (β-fibrin) with weaker self-aggregation characteristics than the normal product (β-fibrin)
produced by release of fibrinopeptides A (FPA) and B (FPB) by thrombin. We investigated
the ultrastructure of these two types of fibrin as well as that of β-fibrin prepared from fibrinogen Metz
(Aα16 Arg→Cys), a homozygous dysfibrinogenemic mutant that does not release FPA. At 14°C and
physiologic solvent conditions (0.15 mol/L of NaCl, 0.015 mol/L of Tris buffer pH 7.4), the turbidity (350
nm) of rapidly polymerizing αβ-fibrin (thrombin 1 to 2 U/mL) plateaued in <6 min and formed a “coarse”
matrix consisting of anastomosing fiber bundles (mean diameter 92 nm). More slowly polymerizing αβfibrin (thrombin 0.01 and 0.001 U/mL) surpassed this turbidity after ≥60 minutes and concomitantly
developed a network of thicker fiber bundles (mean diameters 118 and 186 nm, respectively). Such
matrices also contained networks of highly branched, twisting, “fine” fibrils (fiber diameters 7 to 30 nm)
that are usually characteristic of matrices formed at high ionic strength and pH. Slowly polymerizing βfibrin, like slowly polymerizing αβ fibrin, displayed considerable quantities of fine matrix in addition to
an underlying thick cable network (mean fiber diameter 135 nm), whereas rapidly polymerizing β-fibrin
monomer was comprised almost exclusively of wide, poorly anastomosed, striated cables (mean
diameter 212 nm). Metz β-fibrin clots were more fragile than those of normal β-fibrin and were
comprised almost entirely of a fine network. Metz fibrin could be induced, however, to form thick fiber
bundles (mean diameter 76 nm) in the presence of albumin at a concentration (500 μmol/L) in the
physiologic range and resembled a Metz plasma fibrin clot in that regard. The diminished capacity of
Metz β-fibrin to form thick fiber bundles may be due to impaired use or occupancy of a polymerization
site exposed by FPB release. Our results indicate that twisting fibrils are an inherent structural feature of
all forms of assembling fibrin, and suggest that mature β-fibrin or αβ-fibrin clots develop from networks
of thin fibrils that have the ability to coalesce to form thicker fiber bundles.

Thrombin-Catalyzed fibrin formation begins with the release of fibrinopeptide A (FPA) from the amino
terminus of the Aα chains of fibrinogen1, 2, 3, 4, 5 and is accompanied by the slower release
of fibrinopeptide B (FPB) from Bβ chains. Reptilase, a snake venom enzyme from Bothrops atrox,
removes only FPA,6, 7, 8 release of which is sufficient for fibrin polymerization (α-fibrin) to occur.7, 8, 9

Mature fibrin clots evidently assemble from a network of thin protofibrils that subsequently, under
physiologic solvent conditions, undergo lateral aggregation, causing increased fiber
thickness.10, 11, 12 Since 1947, two extreme forms of three dimensional fibrin networks, namely “fine” and
“coarse,” have been recognized.13 The fine gel structure can be produced at high ionic strength and pH,
is translucent and friable, and consists of a network of thin, highly branched, twisting fibers.14 The coarse
gel structure, which forms at or below physiologic ionic strength and pH, is opaque and easily synerized.
Owing to a strong tendency for lateral association under such conditions, these matrices are
characterized by thick fiber bundles, the thicknesses of which are reflected by turbidity
measurements10, 11, 12, 13,15, 16, 17, 18 and determined in part by the kinetics of fiber growth.11,12,18,19 That is,
slowly forming clots at physiologic pH and ionic strength tend to develop thicker fiber bundles than do
more rapidly forming clots.12,18,20
Some investigators2,3,5,8,21 have suggested that FPB release is essential for lateral fiber growth. Other
studies, however, indicate that this is not the case,10,11,16,22,23 since reptilase cleavage of FPA to form αfibrin results in a coarse matrix whose cables are only moderately narrower than those formed by αβfibrin.10,11,22 The light scattering studies of Müller and co-workers24 also indicated that α-fibrin and αβfibrin were similar with respect to branching tendency and lateral aggregation. Thus, although FPB
release is not strictly required for gelation or for lateral aggregation, its release may increase the rate
and extent of lateral associations. 10,11,16 In additon, fiber slippage is reduced, fiber stiffness is increased,
and branch points in αβ-fibrin fibers are probably reinforced by noncovalent bonding correlating with
FPB release.14,23,25 Mihalyi and Donovan26 recently provided calorimetric data indicating that
noncovalent interactions of the fibrin(ogen) D domains are enhanced by removal of FPB.
Preferential release of fibrinopeptide B by copperhead venom procoagulant enzyme (CVE)27 is sufficient
to cause normal fibrinogen to polymerize.28,29 Based on their gross appearance, these clots tend to be
fine at temperatures <25°C and are readily dissociated at 37°C.28,29 Judging from light scattering
measurements on fibrin clots formed at 20°C and 37°C, it apears that selective cleavage of FPB at low
enzyme concentrations results in the highest branching density and the lowest degree of lateral
aggregation.24
In this study, we used electron microscopy to investigate the three-dimensional structure of β-fibrin
formed from normal fibrinogen and from the homozygous congenital fibrinogen abnormality known as
fibrinogen Metz (Aα Arg 16 → Cys).30, 31, 32 To preserve the structures of these fragile fibrin clots, we
prepared our material using the critical point drying technique33 as recently used for the study of fine
fibrin matrices.14

MATERIALS AND METHODS
Normal fibrinogen fraction 1-2 (>95% coagulable) and fibrinogen Metz fraction 1-2 were purified from
citrated plasma by the method of Blombäck and Blombäck.34 In some experiments, chromatographically
purified normal peak 1 fibrinogen33 was used. As assessed by the position of the fibrinogen band in
NaDodSO4-Polyacrylamide gel electrophoresis (PAGE) (5% acrylamide),36,37 unreduced fibrinogen Metz
molecules were devoid of polymeric forms and the preparation was ~95% pure.
Sulfhydryl titrations of various fibrinogen preparations were carried out either with Ellman’s reagent,
5,5′-dithiobis (2-nitrobenzoic acid) (DTNB),38 or with 3H- or l4C-iodoacetic acid (specific activities 140
mCi/mmol and 11.1 mCi/mmol, respectively). After reaction with the iodoacetate, samples were

extensively dialyzed, dissolved in 10 mL of Aquasol-2 liquid scintillation cocktail (New England Nuclear,
Boston), and radioactivity was subsequently determined in a Packard model 2425 spectrometer.
Freeze-dried human thrombin (H-l), a gift from Dr D. L. Aronson, was reconstituted in H2O and stored
frozen at a concentration of 100 U/mL. CVE was prepared as described by Herzig and co-workers27 and
had an activity of 33 TAME (Nα-p-tosyl-Larginine methyl ester) U/mL. Common chemicals were of
reagent grade.
Fibrinogen samples for fibrinopeptide analyses were brought to a final concentration of 5 mg/mL in a
buffer of 0.15 mol/L NaCl, 0.01 mol/L of Tris pH 7.2 ± 0.1, and incubated in small glass tubes after the
addition of thrombin or CVE. Release of FPA and/or FPB from fibrinogen was measured after overnight
incubation using the high-performance liquid chromatography (HPLC) chromatographic system
described by Kehl and Henschen.39 Specifically, the fibrinopeptides were analyzed with a Varian model
5040 HPLC apparatus on an Ultrasil ODS reverse-phase column (25 cm × 4.6 mm) (Rainin Instrument,
Woburn, MA) using a linear gradient of acetonitrile (12% to 28%) buffered with 25 mmol/L
of ammonium acetate pH 6.0.
αβ-Fibrin or β-fibrin was prepared by addition of thrombin or CVE (0.66 or 0.13 U/mL), respectively, at
14 ± 1°C, to normal fibrinogen, followed by overnight incubation at 14°C. Metz β-fibrin was generated at
14°C or 37°C by addition of CVE (0.66 U/mL) or thrombin (I to 5 U/mL). In some cases, bovine serum
albumin (BSA) (500 μmol/L, final concentration; Sigma Chemical, St Louis) or CaCl2 (5 mmol/L), or both
were included in the clotting mixture.
HPLC determination of fibrinopeptides released from normal β-fibrin under these conditions revealed
the expected presence of FPB and des-Arg FPB and ≤10% of the potentially available amount of FPA.
Metz β-fibrin showed only FPB and des-Arg FPB. For those batches of CVE that contained Aα chain
degradative activity, tosyl lysine chloromethyl ketone (Sigma Chemical) 10−4 mol/L, final concentration,
was added to the clotting mixture prior to CVE addition to block this activity. Turbidity measurements at
350 nm on fibrin clots were carried out at 14 ± 1°C in a Gilford model 240 spectrophotometer equipped
with a jacketed specimen holder.
Certain β-fibrin specimens were subjected to gel-sieving chromatography at 37°C to separate β-fibrin
from a minor αβ-fibrin contaminant.29 In brief, following the incubation period with CVE, the clot was
overlaid with 1 mmol/L of phenylmethylsufonyl fluoride (PMSF) in buffer and incubated in the presence
of this reagent for at least 2 hours. The fibrin was then dissociated by being warmed to 37°C, mixed with
an equal volume of 0.3 mol/L of NaCl, 0.03 mol/L of Tris buffer pH 7.4 ± 0.1 PMSF 10−4 mol/L, and gelfiltered at 37°C through a Sepharose 2B column equilibrated in this same buffer. Early eluting fractions
containing the αβ-fibrin contaminant were discarded, whereas fractions containing “β-fibrin monomer”
eluting at a concentration above six-tenths of the β-fibrin peak height were pooled and stored frozen at
−30°C at concentrations ranging from 400 to 800 μg/mL. For electron microscopy or turbidity
measurements, aliquots of β-fibrin monomer were thawed at 37°C for 30 minutes, diluted 1:1 with H2O,
and then incubated at 14°C for the desired amount of time. Preparations were monitored by NaDodSO4PAGE36,37 to verify whether anticipated fibrinopeptide cleavages had occurred and to determine if other
proteolytic attack had occurred (eg, on Aα chains).
Samples of purified fibrin for negative staining electron microscopy were formed at 14 ± 1°C as 50-μL
drops (50 to 500 μg/mL) in a Petri dish that had been humidified with a moist sponge, incubated for 16

to 18 hours with thrombin or CVE, picked up on glow discharged carbon films, and then negatively
contrasted with 2% (wt/vol) uranyl sulfate. For processing by the critical point drying technique, clots
were picked up on glow-discharged carbon-coated 200-mesh copper grids, fixed
with glutaraldehyde (2.5%, vol/vol) in 0.1 mol/L of HEPES buffer pH 7.0, containing 0.2% (wt/vol) tannic
acid, washed several times with H2O, stained with 0.5% (wt/vol) uranyl acetate, and washed again with
H2O.14 The specimen was then dehydrated in graded ethanol solutions (20% to 100%, vol/vol) and
CO2 critical point dried33 using a Tousimis model 780A critical point drying apparatus (Tousimis Scientific
Instruments, Rockville, MD).
Plasma fibrin clots were prepared from blood that had been drawn into a plastic syringe, immediately
transferred to a centrifuge tube, and then centrifugea at 3,000 g for 3 to 5 minutes to remove cellular
elements. The supernatant plasma was incubated overnight at room temperature, and the resulting clot
was synerized, washed extensively with saline, and fixed overnight at 4°C in 2% (wt/vol) glutaraldehyde
solution in 0.1 mol/L of phosphate buffer pH 7.2. Metz fibrin clots were also prepared without syneresis
from purified Metz fibrinogen at 2 mg/mL. The fixed preparation was incubated for 90 minutes with
2% osmium tetroxide in 0.1 mol/L of phosphate buffer, dehydrated in graded ethanol solutions, and
embedded in Spurr’s low-viscosity medium.40 Thin sections were prepared using a diamond knife and a
Reichert Ultracut ultramicrotome and stained with 5% aqueous uranyl acetate and Sato’s lead citrate
solution.41
Electron microscopy was performed with a Philips model 400 transmission electron microscope at 60 to
120 kV or with the University of Wisconsin high-voltage (1,000 kV) electron microscope at Madison, WI.
Stereo images were made at magnifications of 5,000x to 22,000x at tilt angles of 3° to 6°.

RESULTS
We prepared β-fibrin at 14°C to minimize cleavage of FPA by CVE,28 and we used this same temperature
for polymerization of other forms of fibrin. The standard way of processing fibrin for transmission
electron microscopy (TEM) is to pick up a clot sample by passing a carbon-coated grid through a fibrin
clot. The grid surface is washed subsequently with buffer and uranyl sulfate and then air dried. Samples
processed in this way have been suitable for observing the structure of a normal coarse fibrin
matrix42,43 and for characterizing the structure of certain abnormal fibrins such as fibrinogen Paris
I.44 The Metz clot structure and that of β-fibrin was so fragile, however, that at best we found
discontinuous short strands and occasionally anastomosing fiber bundles and thin fibrils adherent to the
underlying substrate. To preserve the three-dimensional structure of this type of clot, we processed the
sample using the critical point drying procedure.33 This technique has been used for demonstrating
previously unrecognized features of fine clot matrices.

αβ-Fibrin.

Images of critical point dried, rapidly polymerizing αβ-fibrin (thrombin, 1 U/mL) formed at 14°C under
physiologic conditions (ie, I ~0.15, pH 7.4), revealed a coarse matrix consisting predominantly of twisted
anastomosing cables (Fig 1A, Table 1). These cables showed typical cross-striations (~22 nm period)
when viewed at a higher magnification than that shown in Fig 1 (data not shown).*

Fig 1. Stereo images by transmission electron microscopy (TEM) of αβ-fibrin (500 μg/mL) prepared by
incubation overnight at 14°C under “coarse clot” buffer conditions (0.15 mol/L of NaCl. 0.015 mol/L
of Tris buffer, pH 7.4) at the following thrombin concentrations: (A) 1 U/mL; (B) 0.01 U/mL; (C) 0.001
U/mL. Bar = 1,000 nm. The arrows in (C) indicate loosely packed fiber bundles.
Table 1. Fiber Diameter of Thick Fiber Bundles of αβ-Fibrin and β-Fibrin
Preparation
Concentration
n* Fiber Diameter
(μg/mL)
(nm)
Mean
SD Range
αβ-Fibrin (thrombin, 2 U/mL)
50
36 83
±37 50−170
αβ-Fibrin (thrombin, 1 U/mL)
500†
89 92
±39 36−260
αβ-Fibrin (thrombin, 0.01 U/mL)
500
43 118
±59 35−256
αβ-Fibrin (thrombin, 0.001 U/mL)
500
36 186
±90 60−536
β-Fibrin monomer
355
55 212
±80 40−520
β-Fibrin (CVE, 0.66 U/mL)
500
36 87
±30 35−170
β-Fibrin (CVE, 0.13 U/mL)
500
48 135
±73 35−421
2+
Metz β-fibrin + albumin + Ca
500
29 76
±32 39−194
In matrices containing significant amounts of both “fine” and “coarse” networks, there appeared to be
no sharp size transitions in the progression from thin fibers in the fine matrix (7 to 30 nm in diameter)
toward thicker fibers approaching the mean values. For purposes of this analysis, we defined the
diameter of a coarse fiber bundle as ≥35 nm.
*Number of fibers measured.
†Owing to the thickness of the clot in the critical point dried specimen, it seemed tenuous to assume
that areas selected for fiber measurement were representative of the fiber population in the clot. For
that reason, we also prepared thin sections of an imbedded specimen under these same conditions. The
fiber diameter determined from this type of specimen preparation was 92 ± 26 nm, range 37−150 nm.
SD and range of values were lower because we used only the minimum cross-sectional diameter of any
given fiber to avoid including measurement of tangential or oblique sections of fibers in our calculations.
At a 100-fold lower thrombin concentration (0.01 U/mL), the rate of fibrin polymerization was
considerably slowed (Fig 3); nevertheless, the clot ultimately developed considerably greater turbidity
than fibrin formed at 1 U/mL. These observations confirm studies indicating that slow rates of fibrin

polymerization favor higher degrees of lateral aggregation (ie, thicker fiber bundles).12,18,20 At a thrombin
concentration of 0.001 U/mL, clot development proceeded even less rapidly than at 0.01 U/mL although
the turbidity eventually exceeded that of rapidly polymerizing αβ-fibrin. NaDodSO4-PAGE analysis of
fibrin specimens taken at the time of fixation for critical point drying, indicated that complete FPA
release had occurred in all cases, but that in the specimen prepared at a thrombin concentration of
0.001 / mL, only 50% of FPB had been released.

Fig 3. Turbidity measurements on αβ-fibrin. These experiments were carried out under the same
conditions described in Fig 1. Thrombin was added to a final concentration of 1 U/mL. 0.01 U/mL, or
0.001 U/mL; absorbance (A350 nm) was monitored as a function of time.
Consistent with turbidity measurements, fibrin formed at 0.01 U/mL or 0.001 U/mL revealed a network
predominantly composed of large anastomosing fiber bundles that tended to be thicker than those from
rapidly polymerized αβ-fibrin (Fig 1). In addition to the thick cable network, however, there was also a
prominent network of thinner fibrils. This second type of matrix was most prominent at the lowest
thrombin concentration (0.001 U/mL) and consisted of highly branched, twisting fibrils (Fig 4) that
appeared to entrap and merge with large fiber bundles. The thick cables forming under this latter
condition were composed of loosely packed fibrils (arrows, Fig 1C) and did not display the striations
typical of more tightly packed bundles.

Fig 4. Stereo images of fibrin specimens showing extensive fine fibril networks. (A) αβ-fibrin (TEM);
thrombin 0.001 U/mL; (B) β-fibrin (TEM); copperhead venom procoagulant enzyme 0.13 U/ml; (C)
thrombin-generated Metz β-fibrin monomer (HVEM). Bar = 500 nm.) Arrows indicate a typical twisting
thin fibril. Arrowhead (C) points to a relatively short fiber bundle within the predominantly thin fiber
matrix.

β-Fibrin.

β-Fibrin gels formed at 14°C can be dissociated by being warmed to 37°C, and the resulting β-fibrin
monomer can subsequently be polymerized by incubation at room temperature or below.28,29 This
process can be carried out repeatedly on material that has been inactivated with PMSF. Turbidity
measurements on such a β-fibrin monomer preparation (Fig. 5) indicated that the onset of
polymerization was more rapid than that of β-fibrin formed by direct addition of CVE (Fig 6). The initial
rate of turbidity rise of β-fibrin forming at the higher CVE concentration (0.66 U/mL), however, was
about the same as the value for β-fibrin monomer extrapolated to a concentration of 500 μg/mL (ie,
0.06l/min v 0.065/min). Electron micrographs of the β-fibrin monomer clot showed a network of
twisting, occasionally anastomosing cables (Fig 7A). The mean fiber diameter was greater than in any
other type of β-fibrin or αβ-fibrin matrix (Table l).

Fig 5. Turbidity measurements on β-fibrin monomer. Repoly merization at 14°C under standard buffer
conditions of β-fibrin monomer that had been dissociated at 37°C (—) or further processed after
dissociation at 37°C by molecular exclusion chromatography to remove αβ-fibrin contamination (—).
The curves developed by chromatographically processed β-fibrin monomer are in register with those of
unprocessed β-fibrin monomer, suggesting that a small amount of αβ-fibrin contamination does not
materially change the structure of the matrix that forms.

Fig 6. Turbidity measurements on β-fibrin (500 μg/mL). CVE additions, 0.66 or 0.13 U/mL, to
normal fibrinogen at 14°C were made under the same buffer conditions described in Fig 1. Metz β-fibrin
was incubated with thrombin (5 U/mL) at 14°C and allowed to polymerize under the following
conditions: Metz + buffer; Metz + CaCI2, 5 mmol/L; Metz + albumin, 500 μmol/L; Metz + albumin.
500 μmol/L + CaCI2, 5 mmol/L.

Fig 7. Stereo images of β-fibrin clots sampled after incubation overnight at 14°C under the same buffer
conditions described in Fig 1. (A) β-fibrin monomer (high-voltage electron microscopy HVEM)
355 μg/mL; (B) β-fibrin (TEM) 500 μg/mL; copperhead venom procoagulant enzyme (CVE) 0.66 U/mL;
(C) β-fibrin (TEM) 500 μg/mL; CVE. 0.13 U/mL; (D) thrombin-generated Metz β fibrin monomer (TEM),
500 μg/mL. Bars = 1,000 nm. Arrow (C) indicates a loosely packed fiber bundle.
β-Fibrin produced by addition of CVE (Fig 7) formed a network of thick cables frequently displaying
periodic striations (see footnote, page 1075) typical of α-fibrin or αβfibrin bundles. The fiber bundles in
these networks, like the β-fibrin monomer network, anastomosed only occasionally relative to αβ-fibrin
clots. At the highest CVE level (0.66 U/mL), the matrix revealed occasional areas of fine, fibrillar
networks, usually bridging between thick cables (Fig 7B) or appearing to represent an unraveled or
frayed portion of a thick fiber bundle. At a lower CVE level (0.13 U/mL), fiber bundles in the matrix were
more loosely packed (Fig 7C, arrow) and wider than those formed at the higher CVE concentration. In
addition to the predominant thick cable structure, this clot showed a considerable network of fine
twisting fibrils (Fig 7C and Fig 4B).

Metz β-fibrin.

Metz β-fibrin is more transparent, less viscous, and more easily disrupted than normal β-fibrin. In
contrast to normal, Metz β-fibrin formed by direct addition of thrombin or CVE at 14°C or that formed at
14°C from Metz β-fibrin monomer solutions (ie, first incubated with thrombin at 37°C), revealed a matrix
comprised almost entirely of thin, twisting, and highly branched fibrils (Figs 4C and 7D) that occasionally
coalesced to form somewhat thicker, relatively short, uneven bundles. These observations are
consistent with the very low turbidity recorded at 350 nm (Fig 6).
To evaluate the type of Metz fibrin matrix formed in vivo, we prepared fibrin directly from native plasma
and examined thin sections by electron microscopy (Fig 2). Normal fibrin yielded the expected thick,
striated cables (Fig 2A, arrow), whereas Metz fibrin yielded loosely packed fiber bundles that frequently
were sufficiently in register to yield a striated pattern (Fig 2B, arrow). Fibrin aggregation is well known to
accelerate in plasma,45 and this is due in part to effects related to the presence of albumin and
IgG.46,47 The accelerating effect is also accompanied by increased clot turbidity that is attributable, at
least in part, to the presence of albumin or IgG, or both,47 and Ca2+.48,49 To provide an explanation for the
more mature structure of Metz plasma fibrin relative to purified thrombin-generated or CVE-generated
Metz fibrin, we attempted to induce thick fibril formation by allowing thrombin-generated Metz fibrin to
polymerize in the presence of albumin (500 μmol/L) or 5 mmol/L of CaCl2, or both (Fig 6). Measurements
in the presence of albumin showed increased turbidity developing slowly over several hours; this effect
was even more marked when 5 mmol/L of CaCl2 was also present, although addition of CaCl2 alone to
Metz fibrin had little effect (Figs 6 and 2C). Examination and measurement of critical point dried fibrin
specimens confirmed that increased thick bundle formation had occurred in albumin-containing
specimens (cf Fig 2C and 2D). The thick bundles, like the fine fibrils, had a tendency to twist, but periodic
striations were not observed. As assessed by TEM of thin sections, thick fiber bundle formation could
also be induced in Metz β-fibrin formed at a concentration approximating that in plasma (ie, 2 mg/mL)
(data not shown).
Comparison of the ultrastructure of a Metz plasma fibrin clot with Metz fibrin formed in the presence of
albumin or Ca2+ or both (TEM). (A) Thin section of a normal plasma fibrin clot; (B) thin section of a Metz

plasma clot; bar = 500 nm (A and B); (C) critical point dried specimen of Metz fibrin prepared in the
presence of 5 mmol/L of CaCl2; (D) critical point dried specimen of Metz fibrin prepared with albumin
500 μmol/L and CaCI2 5 mmol/L; bar = 500 nm (A and B). Arrows (A and B) point to periodic striations
that occur in thick fiber bundles.

Fig 2. Comparison of the ultrastructure of a Metz plasma fibrin clot with Metz fibrin formed in the
presence of albumin or Ca2+ or both (TEM). (A) Thin section of a normal plasma fibrin clot; (B) thin
section of a Metz plasma clot; bar = 500 nm (A and B); (C) critical point dried specimen of Metz fibrin
prepared in the presence of 5 mmol/L of CaCl2; (D) critical point dried specimen of Metz fibrin prepared
with albumin 500 μmol/L and CaCI2 5 mmol/L; bar = 500 nm (A and B). Arrows (A and B) point to
periodic striations that occur in thick fiber bundles.

Sulfhydryl content.

Gel electrophoretic analysis of fibrinogen Metz, as well as electron micrographs of negatively contrasted
Metz fibrinogen (not shown), revealed that Metz molecules were monomolecular and thus were not
joined by intermolecular covalent (ie, disulfide) bridges. To investigate further whether the cysteine
residues in fibrinogen Metz at position 16 were oxidized to disulfides, we evaluated the titratable
sulfhydryl (SH) content using Ellman’s reagent.38 Normal fibrinogen, which has no free SH groups,50 and
Metz fibrinogen yielded <0.2 mol of titratable SH groups per mole of fibrinogen. We also used a more
sensitive technique to detect the presence of SH groups by labeling with 3H or 14C iodoacetic acid. With
this technique, the titratable SH content of Metz fibrinogen as well as that of normal peak 1 fibrinogen
was 0.01 to 0.02 mol of SH/mol of fibrinogen.

DISCUSSION
Although many EM studies have been made of the structure of α-fibrin and αβ-fibrin, to our knowledge
none have reported on the ultrastructure of β-fibrin. By using the critical point drying technique to
process fibrin clots, we were able to preserve clot structure and obtain high-quality, detailed stereo
images of β-fibrin and Metz β-fibrin and Metz β-fibrin clot networks. Our findings, coupled with
turbidometric analyses, permitted a comparison of the structure of αβ-fibrin with that of β-fibrin and
Metz β-fibrin.
It is clear from our present findings that release of FPB alone can give rise to clots whose features
resemble those of α-fibrin in several important ways: (a) Both types of fibrin tend to form thick twisting
cables displaying typical periodic cross-striations under physiologic buffer conditions. When
polymerization takes place relatively slowly, both types of fibrin develop fine fibrillar network structures

in addition to a relatively thicker cable network. The latter observation is consistent with previous
studies indicating that fiber thickness is determined in part by the kinetics of fiber growth.11,12,18, 19, 20 (b)
The fibrils from both types of fibrin show the characteristic twisting described by Müller and
colleagues14 for fine clots. Regions containing fine fibrillar matrix structures, whether derived from
normal (β-fibrin or αβ-fibrin) or Metz β-fibrin, are not easily distinguishable from the fine matrix formed
by αβ-fibrin at high ionic strength/pH14 or in a slowly polymerizing system under physiologic conditions
(this study).
Twisting is not only a characteristic of native fibrin fibrils (ref. 14 and this study), but is also a prominent
feature of microcrystals and fibrin clots prepared from enzymatically modified fibrinogen.51,52 We infer
from those results and from our present observations that fiber twisting is an inherent feature of fibrin
assembly when polymerization is initiated by release of either FPA or FPB.
Slowly polymerizing αβ-fibrin or β-fibrin networks contain fine fibrillar substructures that are
superimposed on and merge with thick, loosely packed fiber bundle networks. Such structures evidently
reflect an intermediate phase of fibrin assembly during which thick cables coalesce from a fine fibrillar
matrix to form the mature anastomosing cable network. This observation is consistent with the
observations that under physiologic conditions mature fibrin assembly develops over a relatively long
time23 from protofibrils that subsequently undergo lateral aggregation to form thick fiber
bundles.10, 11, 12 The precise mechanism by which this assembly process takes place is not yet known.
Clot turbidity is reportedly a function of the second power of fiber diameter.15,17,53 Therefore, such
measurements are sensitive to the presence of thick fiber bundles but not to fine fiber networks. The
widest cable structures we observed occurred in the coarse β-fibrin monomer clots, yet these gels
ultimately developed lower turbidity than did the rapidly polymerizing coarse αβ-fibrin matrix or any
other β-fibrin or αβ-fibrin network having lower mean fiber widths (Table 1). This seemingly paradoxical
phenomenon may indicate that light scattering per se is not strictly a function of fiber width but may
also be related to factors such as tightness of fiber packing, branching, etc. Further studies combining
electron microscopy with detailed physical and rheological measurements of clot properties should be
most useful in clarifying this issue.
In contrast to turbidity, measurement of clot permeability is a reflection of pore size, coarse clots having
greater permeability than fine clots.15,17, 18, 19, 20 Shah and colleagues17,18 observed that the permeability
of fibrin formed at a low thrombin concentration did not rise in proportion to the increase in fiber
thickness calculated from turbidity measurements. Such observations are consistent with our present
demonstration that slow polymerization (αβ-fibrin or β fibrin) is accompanied not only by increased
fiber thickness, but also by the formation of fine fiber networks. Deductions on clot matrix structure
based on turbidity and permeability measurements depend on the assumption of a uniform population
of network fibers. This is evidently not the case (ref. 17 and this study), especially under circumstances
that are intermediate to the extremes of fine and coarse fiber network formation.
Release of FPA and FPB exposes independent binding sites in the NH2-terminal region of the molecule
which appear to function cooperatively in the aggregation pro-cess.28,29 Release of FPA exposes the “A”
site, which becomes aligned with the complementary “a” site in the D domain of another
molecule.5,21 Similarly, FPB release evidently exposes a “B” polymerization site,28,29 efficient utilization of
which by the complementary “b” site may depend on proper alignment of two D domains in an αβ-fibrin
polymer.21 Substitution of cysteine for arginine at Aα 16 in fibrinogen Metz evidently impairs this

process because Metz β-fibrin, unlike normal β-fibrin, has only a weak tendency for lateral aggregation.
This impairment may be due to the existence of a disulfide bridge at Aα 16.54 The substitution may
impose conformational or steric changes that interfere with proper occupancy or orientation of the
polymerization site unmasked by release of FPB, thus impairing optimal alignment of fibrils into bundles.
Further study of this impairment may lead to new insights into the exact location of the region involved
in the ability of fibrin to form lateral associations with other fibrin molecules.
In contrast to purified Metz fibrin, the Metz plasma clot was less fragile, could be synerized, and showed
a considerable degree of lateral aggregation, even to the extent of forming easily discernible periodic
striations (Fig 7). This “improvement” in Metz clot structure is not surprising since fibrin aggregation in
plasma is associated with increased clot turbidity and increased lateral fiber aggregation.47 When Metz
fibrin was formed at concentrations approaching that in plasma or at an albumin concentration in the
physiologic range (500 μmol/L), we were able to induce an increased degree of lateral fiber association.
This effect was even more pronounced when Ca2+ was also present. We believe that the differences
between purified Metz β-fibrin and plasma Metz β-fibrin structure are largely attributable to the fact
that the plasma environment favors lateral fiber growth, due in part to the relative concentration of
fibrinogen and to albumin or IgG.46,47 Other plasma factors contributing to the strength and structure of
the Metz plasma clot (eg, crosslinking) remain to be explored. In this regard, the Metz subject is not a
severe or spontaneous bleeder, although she often bleeds for prolonged periods
from venipuncture sites and is a habitual aborter.30 Perhaps the relatively mild clinical bleeding that she
manifests reflects the effect that the plasma environment has in enhancing fibrin clot formation.
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